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The link between dysregulated serotonergic activity
and depression and anxiety disorders is well estab-
lished, yet the molecular mechanisms underlying
these psychopathologies are not fully understood.
Here, we explore the role of microRNAs in regulating
serotonergic (5HT) neuron activity. To this end, we
determined the specific microRNA ‘‘fingerprint’’ of
5HT neurons and identified a strong microRNA-
target interaction between microRNA 135 (miR135),
and both serotonin transporter and serotonin recep-
tor-1a transcripts. Intriguingly, miR135a levels were
upregulated after administration of antidepressants.
Genetically modified mouse models, expressing
higher or lower levels of miR135, demonstrated
major alterations in anxiety- and depression-like
behaviors, 5HT levels, and behavioral response to
antidepressant treatment. Finally, miR135a levels in
blood and brain of depressed human patients were
significantly lower. The current results suggest a
potential role for miR135 as an endogenous antide-
pressant and provide a venue for potential treatment
and insights into the onset, susceptibility, and het-
erogeneity of stress-related psychopathologies.
INTRODUCTION
Mood disorders such as major depression are among the most
common health problems worldwide, affecting approximately
10% of the population (Berton and Nestler, 2006; Manji et al.,
2001) and are associated with a large global burden of disease,
according to the World Health Organization (Ustu¨n et al., 2004).
Despite many decades of research, the molecular and cellular344 Neuron 83, 344–360, July 16, 2014 ª2014 Elsevier Inc.mechanisms that underlie depression onset, susceptibility, and
heterogeneity are only partially understood. The treatment
efficacy of available antidepressant drugs is low, as 60%–70%
of patients do not experience remission and 30%–40% do not
show a significant response (Berton and Nestler, 2006; Manji
et al., 2001). Furthermore, available antidepressants require
long periods of administration before relief of symptoms is
observed, and side effects are common and exhibit wide interin-
dividual variability (Wang et al., 2005; Moncrieff and Kirsch,
2005; Masand, 2003). A better understanding of the etiology
and pathophysiology of mood disorders is needed to facilitate
development of novel and improved therapeutics.
The main current hypothesis regarding the etiology of depres-
sion and/or anxiety disorders is of a complex interaction
between environmental factors and genetic predisposition,
possibly suggesting a mechanistic role for epigenetic processes
(Krishnan and Nestler, 2008). Strong comorbidity between
anxiety disorders and depression is frequently reported (Mu¨ller
and Wurst, 2004), and the available pharmacological treatments
for both disorders are similar as well (Baldwin et al., 2005).
Serotonin (5HT), a monoamine neurotransmitter, is produced
in the brain by neurons in the midbrain raphe nuclei (RN) that
project extensively throughout the brain and modulate a variety
of cognitive, emotional, and physiological functions. The link be-
tween dysregulated serotonergic activity and depression or anx-
iety disorders is well established and the levels of 5HT, as well as
the cellular mechanisms responsible for its production, secre-
tion, reuptake, and deactivation, were reported to be dysregu-
lated in depression (reviewed in Meltzer and Maes, 1995; Albert
and Franc¸ois, 2010; Ansorge et al., 2007; Schloss and Henn,
2004). Furthermore, most available antidepressant drugs target
the function of 5HT system-related proteins, resulting in
increased 5HT levels in the brain (Krishnan and Nestler, 2008).
In-depth understanding of the molecular and cellular mecha-
nisms regulating 5HT neuronal functions may contribute to the
development of drugs that are more effective, with shorter func-
tional onset and fewer side effects.
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microRNA 135 and 5HT-Related PsychopathologiesMicroRNAs (miRs) are a subset of endogenous small
(22 nucleotide) noncoding RNA molecules that repress gene
expression posttranscriptionally (Bartel, 2004; Friedman et al.,
2009). Binding of a miR, primarily to the 30 UTR of mRNAs, leads
to direct mRNA destabilization or translational repression, ulti-
mately resulting in reduced protein levels of target genes (Bartel,
2004). Several miR-screening studies have reported that miR
levels in various adult rodents or human brain structures are
affected by a range of behavioral and pharmacological manipu-
lations (for review, see O’Connor et al., 2012). The fine-tuning of
gene expression by miRs can ultimately influence both normal
and pathological behavior, offering an exciting new approach
for studying control of different normal and pathological
behaviors.
Here, we have set out to identify specific miRs that may regu-
late 5HT neuron-related genes and to dissect the role of such
miRs inmodulating depression- and anxiety-like behaviors under
normal and challenged conditions. We determined the specific
miR expression pattern of 5HT neurons and bioinformatically
identified miRs that target, among others, two key transcripts in
the serotonergic network: the 5HT transporter, Slc6a4, and the
5HT autoreceptor, Htr1a. Targeting predictions of these genes’
30 UTRs were further verified by in vitro assays and mutation
studies. miR135 emerged as a prominent regulator of these key
5HT system transcripts andwasdemonstrated to be upregulated
after antidepressant administration. Furthermore, overexpres-
sion or knockdown of miR135 in the RN of adult mice supported
a role for miR135 as an endogenous antidepressant. Finally, we
show data supporting a potential biomarker role for blood
miR135a in human depression and treatment responsiveness.
RESULTS
microRNA ‘‘Fingerprint’’ of 5HT Neurons
5HT neurons were isolated from the rostral brain of ePet-
EYFP mice on embryonic day 12 (E12), and their miR expression
profile was compared to non-5HT cells, obtained from the same
brain area, using miR microarray (Figure 1A). Cell-sorting valida-
tion was performed by comparing the mRNA expression levels
of relevant marker genes. Yfp, the fluorescent marker for the
ePET-positiveneurons,wassignificantlyenriched in the5HTpop-
ulation (Figure 1B), aswas tryptophan hydroxylase 2 (Tph2), a key
enzyme in the production of 5HT (Figure 1C). Glutamate decar-
boxylase 67 (Gad67), the enzyme catalyzing synthesis of GABA,
a common non-5HT neurotransmitter in the RN, was abundant
in the non-5HT cells (Figure 1D). The miR ‘‘fingerprint’’ obtained
from the microarray (Figure 1E) contained 14 (Table S1 available
online) and 27 (Table S2) miRs that were expressed 2-fold more
or less, respectively, in 5HT neurons compared to the non-5HT
neurons. Representative validation of the array results was per-
formed using real-time PCR for miRs highly expressed in 5HT
neurons such as miR375 (Figure 1F) and for miRs expressed at
lower levels in 5HT neurons such as miR135a (Figure 1G).
In order to further study the potential role of miRs as modula-
tors of 5HT neurons, extensive bioinformatics analyses were
performed in a hypothesis-driven manner. Targeting prediction
of known 5HT-related genes expressed in serotonergic neurons
that have been previously demonstrated to be associated withpsychopathologies were bioinformatically crossed with the
microarray results. miR-targeting predictions were performed
using two different web-based algorithms, Target Scan (http://
www.targetscan.org) and MiRanda (http://www.microrna.org),
and were crossed with the list of 91 miRs altered by at
least ±1.5-fold in the 5HT neuron miR array, compared to non-
5HT cells. Several protein-coding target genes expressed in
5HT neurons in the RN were selected, including tryptophan hy-
droxylase 2 (TPH2), the rate-limiting enzyme in 5HT production;
monoamine oxidase A (MAOA), an enzyme that metabolizes 5HT
the 5HT transporter (SERT), which is responsible for 5HT reup-
take (the Slc6a4 gene); and 5HT inhibitory receptor 1a, HTR1A
(the Htr1a gene). Based on the miR array data and the bio-
informatic analysis, the miR-targeting predictions for Slc6a4
and Htr1a were most promising and chosen for further in vitro
validation (Figures 1H and 1I).
miR135 Targets Htr1a and Slc6a4 Transcripts
In vitro luciferase assays were performed to test the miR-target
interaction between the 30 UTR of the tested 5HT-related genes
and the miRs predicted to putatively target these transcripts.
miR135 targeting of Slc6a4 30 UTR (Figures 2A, 2C, and 2D)
and Htr1a 30 UTR (Figures 2B, 2E, and 2F) resulted in
30%–50% repression of translation of these transcripts. Addi-
tionally, significant repression of Htr1a 30 UTR was mediated
by miR335, miR181c, and miR26a (Figure 2B). Due to the
30%–50% repression of miR135 on both Htr1a and Slc6a4, we
focused our studies on these miR-target interactions. Further
bioinformatic analysis revealed that miR135 has three highly
conserved variants: miR135a-1, miR135a-2, and miR135b (Fig-
ures S1A, S1B, and S1C). In addition, miR135 seed match
sequences in theSlc6a4 30 UTRare highly conserved (Figure 2G),
and in one out of the two seed matches in the Htr1a 30 UTR,
strong conservation was observed (Figure 2H). Mutation
studies on the 30 UTR of the Slc6a4 transcript, in which the
miR135 seed match sequence was removed, revealed that
both miR135a and miR135b targeting of Slc6a4 was mediated
via its seed match sequence (Figure 2I). Mutating the Htr1a
miR135 seed matches, individually or together, revealed that
miR135a repressed Htr1a 30 UTR via the distal and not the prox-
imal seed match, while miR135b acts via both predicted sites
(Figure 2J).
RN-miR135a Levels Are Upregulated by
Antidepressants
Since both HTR1A (Savitz et al., 2009) and SERT (Murphy et al.,
2008) are associated with depression and antidepressant
cellular machinery, we sought to examine the regulation of
miR135a expression in response to antidepressant treatment.
The mature miR135a and miR135b differ by only one nucleotide
(Figure 3A), yet were differentially expressed in the RN, as
observed in the real-time PCR results conducted on cDNA
obtained from microdissected RN of adult wild-type mice (Fig-
ure 3B). miR135b was expressed approximately 10-fold less
than miR135a, while the latter was relatively highly expressed,
only 5-fold less than miR124, an abundant miR in the brain
(Lim et al., 2005), and 2.5-fold less thanmiR16, whichwas shown
to have a role in controlling 5HT functions (Baudry et al., 2010)Neuron 83, 344–360, July 16, 2014 ª2014 Elsevier Inc. 345
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levels in the RN thanmiR135b andwas also the variant differently
altered in the 5HT microarray, we focused our regulation studies
on this form. miR135a was expressed also in different brain
nuclei, with relatively high levels in the RN, the hypothalamus,
prefrontal cortex, septum, and ventral hippocampus (Figure S2).
Future studies should assess the role of miR135 endogenously
expressed in other brains regions associated with depression
and anxiety such as the hippocampus and prefrontal cortex.
Next, we tested the levels ofmiR135a inmice exposed to chronic
social defeat, an environmental model used for the induction of
anxiety- and depression-like behaviors (Krishnan et al., 2007)
and to chronic treatment with the tricyclic antidepressant imipra-
mine. Using the social avoidance test, we verified that social
defeat can cause social avoidance and antidepressant adminis-
tration can reverse this, as reported previously (Berton et al.,
2006) (Figure 3D). Indeed, only mice exposed to social defeat
and injected with saline and not those that received imipramine
developed social avoidance, as implied by an interaction ratio
lower that 100% (Figure 3D). Interestingly, chronic social defeat
stress did not alter miR135a levels in the RN; however, imipra-
mine administered chronically (Figure 3E) or acutely (Figure 3F),
both in stressed and nonstressed mice, significantly increased
miR135a expression levels in the RN. Since imipramine is not a
specific 5HT reuptake inhibitor, we further tested the effects of
both acute and chronic administration of the selective serotonin
reuptake inhibitor (SSRI), fluoxetine, and the noradrenaline reup-
take inhibitor (NRI), reboxetine, and found an increase in
miR135a levels in the RN after both acute and chronic SSRI
treatment, yet no differences were observed after the NRI treat-
ment (Figure 3G). The reduction in SERT and HTR1A levels after
antidepressant administration was described elaborately in the
literature and therefore was not tested in this study (SERT re-
viewed in [Schloss and Henn, 2004] and HTR1A reviewed in
[Albert and Franc¸ois, 2010]).
miR135a Overexpression Specifically in 5HT Neurons
Reduces Anxiety- and Depression-like Behaviors after
Social Defeat
To further explore the role of 5HT-miR135 in vivo, we established
a mouse model that specifically overexpresses miR135a in 5HT
neurons of the RN (miR135a OE). Mice expressing Cre recom-
binase specifically in the RN 5HT-positive neurons (ePet-Cre)
(Scott et al., 2005) were crossbred with a transgenic mouse
line carrying a conditional miR135a cassette (Anderegg et al.,Figure 1. MicroRNA ‘‘Fingerprint’’ of 5HT Neurons
(A) Schematic illustration of the experimental design for determining 5HT neuro
dissected and FACS sorted to 5HT-YFP-positive and -YFP-negative cells. miR ex
microarray. RN, Raphe nucleus; DR, dorsal Raphe; MR, median Raphe.
(B–D) Validation of cell phenotype by real-time PCR indicating that Yfp (B) and Tp
Gad67 a GABAergic marker, was significantly higher in non-5HT cells (D).
(E) Graphic illustration of differentially expressedmiRs in 5HT neurons. Lowest nor
average log intensities (MA plot). The gray bar represents a fold change of 2.
(F and G) Validation of array results by real-time PCR indicating increased levels o
to non-5HT cells.
(H and I) Venn diagrams representing bioinformatics predictions for Slc6a4 (H) a
testing. The numbers represent the amount of miRs predicted to target each gene
bars represent mean ± SEM. **p < 0.01, ***p < 0.001.2013) (Figure 4A). As controls, we used mice positive for the
miR135a overexpression transgene and negative for the ePet-
Cre. miR135a expression level in the RN of miR135a OE mice
was tested by real-time PCR and was demonstrated to be over-
expressed by approximately 2-fold compared to control mice
(Figure 4B). Overexpression levels of miR135a in this mouse
model were similar to those measured in the RN of mice after
SSRI administration. Additionally, the levels of miR135 target
genes SERT (Figures 4C, 4E, and 4F), and to a lesser extent
HTR1A (Figure 4D) were reduced in the RN of miR135a OE
mice compared to control mice, demonstrating in vivo repres-
sion of miR135 target genes.
The miR135a OE and their littermate controls were behavior-
ally characterized in tests for anxiety- and depression-like
behaviors, under ‘‘baseline’’ conditions or after chronic social
defeat protocol (different groups of mice). Under ‘‘baseline’’
conditions, no differences were observed between miR135a
OE and control mice in tests for anxiety- and depression-like
behaviors (Figures 4G–4L, left bars, and Figure 4M). However,
miR135a OE mice demonstrated significant resiliency to the
effects of chronic social defeat. In the dark-light transfer test,
miR135a OE mice exposed to social defeat spent more time in
light (Figure 4G), visited the lit compartment more frequently (Fig-
ure 4H), and traveled longer distance in light (Figure 4I) relative to
control mice. The behavioral performance of the miR135a OE
mice did not significantly differ after the social defeat protocol.
In contrast, control mice demonstrated significant increases in
anxiety-like behaviors in all measured parameters of the dark-
light test after social defeat (Figures 4G–4I). Similar results
were observed in the elevated plus-maze test, as control mice
that were exposed to social defeat spent less time (Figure 4J),
had fewer visits (Figure 4K), and traveled less distance (Figure 4L)
in the open arms compared to miR135a OE mice tested under
the same conditions. No significant differences between ‘‘base-
line’’ and stress conditions were observed in the miR135a OE
group. Similar results were observed in tests assessing depres-
sion-like behaviors. While no differences were observed under
‘‘baseline’’ conditions (Figure 4M), when tested after chronic
social defeat, miR135a OE mice exhibited significantly less
immobility time in the forced swim test compared to controls
(Figure 4N), which is interpreted as decreased depression-like
behavior or increased coping-like behavior. Interestingly, control
mice tested after social defeat showed immobility time similar to
those of mice tested under ‘‘baseline’’ stress conditions, a phe-
nomenon reported by others (Krishnan et al., 2007). Thesenal microRNA ‘‘fingerprint.’’ ePet-EYFP mouse embryo (E12) hindbrains were
pression from the two populations was compared using the Agilent microRNA
h2 (C) were significantly enriched in 5HT compared to non-5HT cells and that
malized values are depicted as ln2-fold change of spot intensity plotted against
f miR375 (F) and decreased levels of miR135a (G) in the 5HT neurons compared
nd Htr1a (I) with 5HT microarray data and the miRs chosen for further in vitro
by the different databases and in the array, individually and overlapping. Error
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Figure 2. miR135 Targets Htr1a and Slc6a4 In Vitro
(A) Luciferase reporter assay results demonstrated that miR135a and miR135b target Slc6a4 30 UTR. A strong trend for targeting by miR16 was also observed.
(B) Luciferase reporter assay results indicating miR135a, miR135b, miR335, miR181c, and miR26a target Htr1a 30 UTR.
(C–F) Nucleotide base pairing of miR135a (C) and miR135b (D) with Slc6a4 30 UTR, and of miR135a (E) and miR135b (F) with Htr1a 30 UTR.
(G and H) Slc6a4 (G) and Htr1a (H) 30 UTRs conservation of miR135 seed match.
(I) Mutation in miR135 seed match in Slc6a4 30 UTR blocked the inhibitory effect of miR135a and miR135b.
(J) Mutation in miR135 seed matches in Htr1a 30 UTR, individually or both, indicate that miR135b targets Htr1a via both seed matches, while miR135a targets
Htr1a only by seed match number 2. Error bars represent means ± SEM. #p < 0.07, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3. miR135a Is Upregulated in Adult
Mouse RN after Antidepressant Treatment
(A) Alignment between mature miR135a and
miR135b indicating one nucleotide difference.
(B) Expression levels of miR135a and miR135b in
the mouse RN demonstrating 10-fold higher levels
of miR135a (n = 8).
(C) Expression profile of several miRs in adult
mouse RN indicating miR135a was approximately
five times less abundant than miR124 and 2.5-fold
less than miR16 (n = 8).
(D) Mice exposed to social defeat demonstrated
increased social avoidance unless treated with
chronic imipramine. Interaction ratio was calcu-
lated as time spent in the zone near the nonfamiliar
mouse divided by the time spent in the same zone
during habitation multiplied by 100 (n = 8–11 in
each group).
(E and F) miR135a levels were upregulated in the
RN after chronic (E) or acute (F) imipramine
administration and were unchanged after expo-
sure to chronic social defeat protocol (n = 8–11 in
each group).
(G) SSRI and not NRI, after either acute or chronic
administration, caused a significant increase in
miR135a levels in the RN (n = 7–8 in each group).
Error bars represent means ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001.
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microRNA 135 and 5HT-Related Psychopathologiesdifferences could not account for changes in locomotor activity,
since the distance traveled in the open field was similar in both
genotypes (Figure 4O). Taken together, overexpression of
miR135a specifically in 5HT neurons protected against the
adverse effect of chronic stress on anxiety- and depression-
like behaviors.
Knockdown of miR135 in Adult Mice RN Increased
Anxiety-like Behaviors and Decreased the Response
to Antidepressants
To determine the importance of miR135 endogenous levels in
mediating anxiety- and depression-like behaviors and response
to antidepressant treatment, we established a lentiviral-based
system to specifically knock down (KD) endogenous miR135 in
the RN of wild-type mice.
Expression plasmid containing a miR135 inhibitor (miRNA
capture; Figure 5A) or control sequence were subcloned into
a lentiviral construct containing the H1 promoter and the GFP
reporter (Figure 5B) to allow constitutive expression of the
miR135 capture sequence. The efficiency of expression plasmidNeuron 83, 344–containing amiR135 inhibitor to suppress
the target gene was tested in vitro using
luciferase assay. A miR135 inhibitor
expression plasmid was cotransfected
into HEK293 cells with a miR135 precur-
sor expression plasmid and a miRNA
target sequence expressing Slc6a4 30
UTR (Figure S3A) or Htr1a 30 UTR
(Figure S3B) downstream to a luciferase
sequence. The result showed that
miR135 suppressed the luciferase activ-ity from theSlc6a4 30 UTR (Figure S3B) and theHtr1a 30 UTR (Fig-
ure S3B), and this suppression effect was blocked by the intro-
duction of the inhibitor against miR135. Additionally, the
efficiency of the lentiviruses, produced from these constructs,
to suppress the expression of the target genes Htr1a and
Slc6a4 was tested in vitro by infecting RN46A cells, which
endogenously express Htr1a, Slc6a4, and miR135. RN46A cells
infected with miR135 KD lentiviruses expressed significantly
lower levels of both miR135a and miR135b and higher levels of
Htr1a and Slc6a4mRNA, as tested by real-time PCR, compared
to cells infected by the KD control lentiviruses (Figure 5C).
Wild-type adult mice RN were infected with either miR135
KD or control lentiviruses. Infection accuracy was subsequently
verified using GFP immunohistochemistry (Figure 5D). Further-
more, miR135 KD lentivirus infection led to increased SERT
protein levels in vivo (Figures 5E and 5F), as measured by
western blot analysis performed on RN tissue. The accuracy
of injection site and of the microdissection was confirmed by
immunoblotting for GFP coexpressed by the lentiviruses for
miR135 KD (Figure 5E).360, July 16, 2014 ª2014 Elsevier Inc. 349
(legend on next page)
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viruses were assessed behaviorally using tests for anxiety- and
depression-like behaviors. In the dark-light transfer test, the
miR135 KD mice demonstrated a significant increase in anxi-
ety-like behavior compared to control-injected mice (Figures
5G–5J). The miR135 KDmice spent less time (Figure 5G), visited
less (Figure 5H), and walked shorter distances in the lit compart-
ment (Figures 5I and 5J). Similarly, in the elevated plus-maze
test, the miR135 KD mice demonstrated increased anxiety-like
behaviors compared to control-injected mice. The miR135 KD
mice showed a tendency to spend less time (Figure 5K), visit
less (Figure 5L), and travel significantly less distance (Figures
5M and 5N) in the open arms of the maze (Figures 5M and 5N).
Depression-like behaviors of the miR135 KDmice were tested
both under ‘‘baseline’’ conditions and after SSRI treatment. In
the forced swim test, no differences were observed between
the groups under ‘‘baseline’’ conditions (Figure 5O). However,
after SSRI administration to the same group of mice, miR135
KD mice were significantly more immobile compared to con-
trol-injected mice (Figure 5O), suggesting an important role for
endogenous RN-miR135 levels in mediating SSRI-induced anti-
depressant effects. The incomplete block of miR135 KD of the
antidepressant effect could be explained by the partial reduction
in miR135 levels (knockdown but not knockout). Reduced levels
of miR135 in the RN did not affect the locomotor activity of these
mice as measured by total distance traveled in the open-field
test (Figure 5P).
miR135a Overexpression Altered 5HT Levels
and Metabolism
To evaluate whether changes in miR135a levels are also re-
flected in the tissue concentrations of central 5HT and its
turnover, we microdissected the RN subdivisions and the brain
regions innervated by these areas from the miR135a OE mouse
model and control littermates. Figures 6, S4, and S5 depict
tissue concentrations of 5HT and the 5HT metabolism (5HIAA/
5HT ratio) in these mice under ‘‘baseline’’ conditions and after
the social defeat protocol.
Tissue concentrations of 5HT and the 5HT metabolism within
an anxiety- and depression-related neural circuit were influ-
enced by the miR135a genotype, as well as the social defeatFigure 4. Overexpression of miR135a Specifically in 5HT Neurons Cau
(A) Schematic illustration of miR135a conditional overexpression mouse mode
miR135a and GFP sequences were crossed with the ePet-Cre recombinase mic
neurons. Littermate mice carrying only the transgene for miR135a served as con
(B) miR135a expression levels in the RN were upregulated by approximately 2-fo
(C–F)miR135 target genes, SERTmRNA (C) and protein (E and F) and HTR1AmRN
(n = 7–11 for mRNA, n = 3–4 for SERT protein).
(G–I) In the dark-light transfer test, no differences were observed between miR13
after chronic social defeat, control mice demonstrated increased anxiety-like beh
(H), and traveled a shorter distance in light (I). The behavioral performance of the m
(J–L) Similarly, in the elevated plus-maze test, control mice that were exposed to s
less distance (L) in the open arms, compared to control mice tested under ‘‘ba
conditions were observed in the miR135a OE group.
(M and N) In the forced swim test, no significant differences were observed betw
tested after chronic social defeat, miR135a OE mice demonstrated decreased im
(O) No differences in locomotion activity were observed between the miR135a OE
test (n = 7–11 in each group in behavioral data). Error bars and line graphs repremanipulation. miR135a OE mice had decreased tissue 5HT con-
centrations and increased 5HT metabolism, a pattern consistent
with increased 5HT turnover, in brain regions implicated in regu-
lation of anxiety-related behavior (Gardner et al., 2005; Hale and
Lowry, 2011; Lowry, 2002) and stress resilience (Deakin and
Graeff, 1991; Graeff et al., 1996), such as the prelimbic cortex
(PrL), infralimbic cortex (IL), basolateral amygdala (BLA), CA1 re-
gion of the ventral hippocampus (CA1V), subiculum (S), bed nu-
cleus of the stria terminalis (BNST), central nucleus of the amyg-
dala (CeA), dorsal, ventral, caudal, and interfascicular parts of
the dorsal raphe nucleus (DRD, DRV, DRC, DRI), and median
raphe nucleus (MnR) (Figures 6, S4, and S5). These results are
in line with the decrease of Htr1a and Slc6a4 expression in
miR135a OEmice (Figure 4) under ‘‘baseline’’ conditions, effects
that would be expected to result in increased serotonergic
neuronal firing rates and serotonergic signaling, respectively.
Social defeat decreased tissue 5HT concentrations and
increased 5HT metabolism in anxiety-related brain regions in
control mice, a pattern consistent with increased 5HT turnover,
including the PrL and BNST (Figures 6 and S5), persistent with
previous studies demonstrating social defeat-induced activation
of anxiety-related subsets of serotonergic neurons in the DRD
and DRC (Gardner et al., 2005). These effects of social defeat
were prevented in miR135a OE mice, suggesting a mechanistic
explanation for the behavioral resiliency to chronic stress
observed in these mice (Figure 4).
miR135a Levels in the Blood and Brain Are
Downregulated in Depressed Patients
Since circulatingmiR levels were shown to correlate with disease
states (Reid et al., 2011), we tested whether blood miR135a
levels are altered in depressed human patients. Relative levels
of miR135a and miR16 were tested in two sets of human blood
samples, in which their clinical manifestations and response to
treatment were previously reported. The first compared
depressed patients to matched healthy controls (detailed
description in Menke et al., 2012) and the other measured
changes in miRs levels over time within depressed patients
receiving either 3 months of SSRI treatment or cognitive
behavioral therapy (CBT) (detailed description in Dunlop et al.,
2012). miR135a levels were robustly reduced in currentlyse Behavioral Resiliency to Social Defeat
l. Transgenic mice with floxed transcriptional STOP sequence upstream to
e. Double transgenic mice overexpress miR135a specifically in 5HT-positive
trols.
ld in miR135a overexpressing (OE) mice compared to controls.
A (D) were downregulated inmiR135aOEmice compared to control littermates
5a OE mice and their control littermates under ‘‘baseline’’ conditions; however,
avior and spent less time in light (G), visited the lit compartment less frequently
iR135a OEmice did not significantly differ following the social defeat protocol.
ocial defeat spent less time (J), had a smaller number of visits (K), and traveled
seline’’ conditions. No significant differences between ‘‘baseline’’ and stress
een the groups when tested under ‘‘baseline’’ conditions (M); however, when
mobility compared to control littermates (N).
and control littermates asmeasured by total distance traveled in the open-field
sent means ± SEM. # p% 0.07; *p < 0.05, **p < 0.01, ***p < 0.001.
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microRNA 135 and 5HT-Related Psychopathologiesdepressed patients (mean Hamilton Depression Rating Scale
[HRDDS] = 24.3 [SD: 5.3], i.e., with moderate-to-severe depres-
sive symptoms) compared to controls (Figure 7A), while a
nonsignificant reduction in miR16 levels was observed (Fig-
ure 7B). Comparing miR135a blood levels in depressed patients
before and after 3 months of SSRI treatment or CBT revealed a
significant increase in miR135a levels after CBT (Figure 7C). No
effect was observed in the same blood samples for miR16 levels
(Figure 7D). These results suggest miR135a levels in human
blood as a possible biomarker for depression state and response
to treatment, yet further studies with larger patient cohorts are
needed.
Moreover, in order to test whether miR135 is dysregulated in
the depressed human brain, we tested miR135 levels in different
subnuclei of the raphe in postmortem tissue obtained from
depressed suicide victims and controls described in detail in
Merali et al. (2006). miR135a and miR16 levels were tested in
five subnuclei: the dorsal raphe (RN), raphe magnus (RM),
pontine raphe, median raphe, and the medullary raphe (raphe
pallidus and obscurus combined). Differences were detected
only in the RN (Figures 7E and 7F) and the RM (Figures 7G and
7H), where miR135a (Figures 7E and 7G) and miR16 (Figures
7G and 7H) were significantly lower in suicide victims compared
to controls. These results suggest that miR135 might play a role
also in the raphe of the human brain in depression.
DISCUSSION
In the current study, we elucidated the role of a specific
microRNA in regulating central 5HT system activity, under
‘‘baseline’’ and challenged conditions. We determined the
unique ‘‘fingerprint’’ of miRs expression in serotonergic neurons
and bioinformatically identified several 5HT-linked target genes.
In vitro luciferase assays and mutation studies revealed a strong
repressive effect for miR135 on both Slc6a4 and Htr1a tran-
scripts. Intriguingly, miR135a levels in the RN were robustly up-
regulated after acute or chronic SSRI administration. Genetically
modified mouse models, expressing higher or lower levels of
miR135, demonstrated major alternations in anxiety- and
depression-like behaviors, 5HT levels and metabolism, and
behavioral response to antidepressant treatment. Finally,Figure 5. Knockdown of miR135 in the RN of Adult Mice Cause
Antidepressants
(A) Schematic illustration of ‘‘miR135 capture’’ structure.
(B) Schematic illustration of miR135 KD and control viral vectors.
(C) miR135 KD lentivirus infection decreased miR135a and miR135b levels an
endogenously express these genes.
(D) Brain sectionmap showing the site of injection, adapted from themouse brain a
mice infected with miR135 KD lentiviruses (right).
(E and F) miR135 KD in the RN of adult mice lead to an increase in SERT protein
(G–J) In the dark light transfer test, miR135 KD mice spent less time (G), had f
compared to control injected mice.
(K–N) In the elevated plus-maze test, miR135 KD mice demonstrated a tendency
(M and N) in the open arms.
(O) In the forced swim test, miR135 KD mice did not differ in their immobility tim
tested 30 min after SSRI administration, miR135 KD mice demonstrated increas
(P) No significant differences in locomotor activity between miR135 KD and contr
test (n = 10–11 in each group in behavioral data). Error bars represent means ± SmiR135a levels in the blood and brain of depressed human
patients and response to treatment were presented.
The use of the ePet-EYFP mouse model for the isolation of
5HT and non-5HT cells from the mouse RN allowed us to deter-
mine the specific miRs profile of serotonergic neurons. This
approach was successful and informative, yet in order to effi-
ciently sort the 5HT-positive neurons from the mouse RN, we
used embryonic and not adult brain tissue. Therefore, part of
the miRs presented in the 5HT miRs profile may be relevant to
developmental processes and not adult 5HT neuronal functions.
Interestingly, miR375, commonly associated with pancreatic
beta cell differentiation, was robustly expressed in 5HT neurons
compared to non-5HT cells, supporting the suggested common
developmental path of these tissues (Baroukh and Van Obber-
ghen, 2009; Ohta et al., 2011).
Bioinformatic analysis suggested several putative miR-target
interactions between the Htr1a and Slc6a4 30 UTRs and miRs
differentially expressed in the 5HT microarray. HTR1A and
SERT have been shown to play a major role in the serotonergic
system function, in depression and anxiety disorders, and in
the response to antidepressants (reviewed by Murphy et al.,
2008; Savitz et al., 2009). HTR1A is an inhibitory G protein-
coupled receptor that is expressed as an autoreceptor on
5HT-producing cells and postsynaptically across the brain of
5HT projection sites. Stimulation of HTR1A autoreceptors in-
hibits serotonergic neuronal firing and the release of serotonin
and has been postulated to be one of the causes for the thera-
peutic lag that is commonly reported for most serotonergic anti-
depressants such as SSRIs (Savitz et al., 2009). SERT is a
plasma membrane transporter that terminates 5HT action by re-
cycling it from the synaptic cleft into presynaptic neurons, in a
sodium-dependent manner (Homberg and Lesch, 2011). SERT
is the direct target of most commonly used antidepressants,
either the former generation of tricyclic antidepressants that
inhibit different monoamine reuptake transporter activities
including SERT or the more specific SSRIs (Schloss and Wil-
liams, 1998). Decreased activity of both SERT and the presynap-
tic HTR1A would be expected to increase 5HT levels in the brain,
which are consistent with antidepressant action and decreases
in depressive symptoms (reviewed in Albert and Franc¸ois,
2010; Ansorge et al., 2007; Meltzer and Maes, 1995; Schlossd Increased Anxiety-like Behavior and Attenuated Response to
d increased Htr1a and Slc6a4 mRNA expression levels in RN46a cells that
tlas (Paxinos and Franklin, 1997) (left) andGFP immunostaining in DRD of adult
(E and F) as measured in GFP-positive samples (E) (n = 4–5 in each group).
ewer visits (H), and traveled less distance (I and J) in the light compartment,
to spend less time (K), had fewer visits (L), and travel significantly less distance
e from control mice when tested under ‘‘baseline’’ conditions; however, when
ed immobility time, indicating attenuated response to antidepressants.
ol mice were observed as measured by total distance traveled in the open-field
EM. #p < 0.07, *p < 0.05, **p < 0.01, ***p < 0.001.
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as significant repressors of both Slc6a4 and Htr1a transcripts.
Mutation studies further demonstrated the importance of
miR135 seed binding sites in the Htr1a and Slc6a4 30 UTRs in
mediating the observed miR135 repressive effects. SNPs in
the 30 UTR of human Slc6a4 and Htr1a, previously reported for
these genes (Piva et al., 2010), are not withinmiR135 seedmatch
sequences.
Several microRNA screening studies have reported that
microRNA levels in various adult rodent or human brain struc-
tures are affected by a range of behavioral and pharmacological
manipulations (Kocerha et al., 2009; Kye et al., 2011). Stressful
challenges were shown to alter miR expression in different brain
sites using different paradigms (Rinaldi et al., 2010; Smalheiser
et al., 2011; Uchida et al., 2008). We previously demonstrated
the involvement of miR34 in the regulation of anxiety-like behav-
iors (Haramati et al., 2011), while miR-22, miR-138-2, miR-148a,
and miR-488 were associated with panic disorder (Muin˜os-Gi-
meno et al., 2011). Studies using mice, presented in the current
manuscript, revealed a clear upregulation of miR135a after anti-
depressant administration. Further comparison of SSRI and NRI
antidepressants demonstrated an SSRI- but not NRI-specific
effect, further suggesting a role for miR135a in the biology of
5HT neurons. While chronic stress is associated with increased
susceptibility to the development of depression, surprisingly,
chronic stress conditions did not affect miR135a levels in the
RN. miR16 was shown to target Slc6a4 and to have a role in
antidepressant response (Baudry et al., 2010), while lithium
administration was shown to alter miRs expression (Creson
et al., 2011; Zhou et al., 2009). An association was found
between variants in miR182 (Saus et al., 2010) and miR30e
(Xu et al., 2010) in major depression patients, and miRs ex-
pression was altered in the prefrontal cortex of patients with
suicidal depression (Smalheiser et al., 2012). Additionally, a
polymorphism in serotonin receptor 1Bmoderates the regulation
by miR96 and associates with aggressive behaviors (Jensen
et al., 2009).
To further support a role for miR135 as an endogenous antide-
pressant, we conducted a series of experiments in which we
manipulated miR135 levels in vivo and assessed the effects on
animal behavior. The transgenic mouse model that overex-
pressesmiR135a specifically in 5HT neurons, in levels equivalent
to those observed after antidepressant treatment, showed a
strong protective effect from the adverse behavioral effects of
chronic social defeat. These results resembled the effect
observed when HTR1A (Bortolozzi et al., 2012) or SERT (ThakkerFigure 6. Overexpression of miR135a in 5HT Neurons Alters 5HT Levels
5HT Reduction
(A, D, G, J, and M) Schematic illustration of microdissection sites from miR135a
defeat. (PrL, prelimbic cortex; BLA, basolateral amygdala; CA1V, hippocampu
nucleus. Section map adopted from Paxinos and Franklin [1997].)
(B, E, H, K, and N) 5HT levels as measured by HPLC in different brain sites reveale
stress conditions. Additionally, 5HT levels were downregulated in control mice e
observed in miR135a OE 5HT mice.
(C, F, I, L, andO) 5HTmetabolism calculated as the ratio between the levels of them
to controls in baseline stress conditions. Furthermore, 5HT metabolism was redu
social defeat compared to control mice from the same genotype. In the PrL, DRV
defeat compared to baseline conditions (n = 5–11 in each group). Error bars repet al., 2005) were knocked down using siRNA approaches,
showing reduced depression-like behaviors. In contrast, the
developmental knockout mouse models for HTR1A (reviewed
in Savitz et al., 2009) and SERT (reviewed in Holmes et al.,
2003) showed paradoxical increases in anxiety- and depres-
sion-like behaviors, which were suggested to be mediated by
developmental compensatory changes. In addition to HTR1A
and SERT, it is bioinformatically apparent that miR135a may
affect other transcripts that are associated with the serotonergic
system functions, which possibly contribute to the observed
phenotypes. Among others, the predicted miR135 targets
include the following 5HT and affective disorder-related
genes: inositol monophosphatase (IMPA1), glycogen synthase
kinase-3beta (GSK3B), ankyrin 3 (ANK3), glutamate receptor,
ionotropic, AMPA3 (GRIA3), potassium intermediate/small
conductance calcium-activated channel, subfamily N, member
3 (KCNN3), and nitric oxide synthase 1 (neuronal) adaptor protein
(NOS1AP) (see Table S6 for additional putative miR135 target
genes associated with stress, the 5HT system, and neuropsychi-
atric disorders).
Using a complementary approach, we knocked down the
levels of miR135 specifically in the RN of adult wild-type mice
using lentiviruses and assessed the effects on mouse behavior.
In contrast to the behaviors observed by the mice that overex-
press miR135a, reduced levels of this miR caused a robust
increase in anxiety-like behavior and an attenuated response
to antidepressants. These results support an important role for
basal miR135 endogenous levels inmaintaining intact responses
to challenge under ‘‘baseline’’ conditions and its essential role in
the mechanism of antidepressant action (Richardson-Jones
et al., 2010). These findings are in agreement with studies
describing a polymorphism in the human Htr1a gene that was
associated with higher HTR1A autoreceptor binding and
increased anxiety and depression (Fakra et al., 2009). In
contrast, lower expression levels of SERT, due to a shorter pro-
moter variant, were reported to be associated with increased
anxiety and depression and reduced responses to antidepres-
sants (Homberg and Lesch, 2011).
Further support for a role of miR135 in 5HT circuits emerged
from the HPLC data indicating a robust alteration in 5HT levels
and its metabolism across the brain of the miR135a OE mice.
5HT levels were lower, while 5HT metabolism was higher, in
the miR135a OE mice compared to controls under ‘‘baseline’’
stress conditions both in subnuclei of the raphe where 5HT is
synthesized and in the projection sites important for controlling
anxiety- and depression-like behaviors. This pattern of changeand Metabolism across the Brain and Blocks Social Defeat-Induced
OE and control mouse brains under baseline conditions or after chronic social
s CA1 ventral; DRV, dorsal raphe nucleus, ventral part; MnR, median raphe
d decreased 5HT levels in miR135a OE mice compared to controls in baseline
xposed to social defeat compared to baseline stress conditions, an effect not
etabolite 5HIAA to 5HT levels was upregulated inmiR135aOEmice compared
ced in the BLA, CA1V, DRV, and MnR in miR135a OE 5HT exposed to chronic
and MnR 5HT metabolism was upregulated in control mice exposed to social
resent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 7. Lower Levels of miR135a in the Blood and Brain of Human Depressed Patients
(A) miR135a levels in total blood of depressed human patients were reduced compared to those of healthy controls.
(B) miR16 blood levels did not differ significantly between depressed to controls (n = 11–12 in each group).
(C) Depressed patients treated for 3 months with cognitive behavioral therapy (CBT) showed a significant increase in total blood miR135a levels compared to
patients receiving SSRI medication.
(D) miR16 levels were similar in both time points in all groups of patients (n = 11 in each group).
(E–H) miR135a (E andG) andmiR16 (F andH) in the dorsal raphe RN (E and F) and raphemagnus RM) (G andH) were lower in suicide victims compared to controls
(n = 4–9 in RN and n = 6–11 in RM in each group).
(I) Schematic representation of a suggested model describing the involvement of miR135 in regulating serotonergic synapse components under normal con-
ditions (top), depression (middle), and following antidepressant administration (bottom). Error bars represent means ± SEM. *p < 0.05, ***p < 0.001.
Neuron
microRNA 135 and 5HT-Related Psychopathologiesin 5HT levels and 5HT metabolism is consistent with increased
serotonergic neuronal firing and increased serotonergic
signaling in miR135a OE mice. These differences could be a
result of compensatory changes associated with the overex-
pression of miR135a from development through adulthood.
However, despite the low ‘‘baseline’’ 5HT levels, the mice
demonstrate normal behaviors under ‘‘baseline’’ conditions,
probably due to a more active 5HT system, as can be depicted
by their higher 5HT metabolism at ‘‘baseline’’ conditions.
Conceivably, lower expression levels of SERT and HTR1A that
function as inhibitors of 5HT secretion in the RN enable the
mice to function normally with lower levels of 5HT. Interestingly,356 Neuron 83, 344–360, July 16, 2014 ª2014 Elsevier Inc.chronic stress caused a decrease in 5HT levels accompanied by
an increase in 5HT metabolism in some brain areas of control
mice, as expected, while in the miR135a OE mice these effects
were not observed. These changes may provide a mechanistic
explanation for the behavioral resiliency to chronic stress
observed in the miR135a OE mice.
The possible use of circulating miRs as a noninvasive
biomarker for pathological conditions is a rising field and is
supported by relatively high levels and stability of miRs in the
circulation. While little is known about the role and origin of the
extracellular miRs, circulating miRs have been associated with
pathophysiological states, such as different types of cancer,
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microRNA 135 and 5HT-Related Psychopathologiesheart diseases, oxidative liver injury, sepsis, pregnancy, and
more (Reid et al., 2011). Few studies haves reported correlations
between peripheral miRs expression levels and human depres-
sion (Belzeaux et al., 2012; Bocchio-Chiavetto et al., 2013; Li
et al., 2013). In the current study, the levels of miR135a in the
blood of depressed patients were determined and a decrease
in miR135a levels in the blood of depressed patients, compared
to match controls, was observed. These findings are in line with
our data from animal models indicating miR135 to be an endog-
enous regulator of mood and vulnerability to depression and
suggest miR135a as a possible biomarker for depression state
and possibly for response to treatment. While the observed in-
crease in miR135a with treatment in peripheral blood of patients
is promising, the lack of congruence between the treatments in-
dicates that additional studies in larger patient cohorts are
needed.
Further support for the possible role of miR135 in human
depression arrived from the postmortem analysis of subregions
of the raphe nuclei, demonstrating lower levels of both miR135
and miR16 in the RN and MR subnuclei of suicide victims
compared to controls. Interestingly, pathophysiology of the
serotonergic RN was evident in depressed suicide patients,
while the other raphe subregions, which did not show alteration
in miRs levels, are not directly associated with the 5HT-depres-
sion circuit (Hornung, 2003).
Additional intriguing support for the possible role of miR135
in the etiology and pathophysiology of human mood disorders
rises from genomic data indicating that miR135a1, miR135a2,
and miR135b genes are all located within loci for susceptibility
to bipolar affective disorder and major depressive disorder.
The miR135a1 gene is located on chromosome 3p21.1 in
proximity to the SNPs rs2251219 and rs1042779 identified
in genome-wide associations andmeta-analysis of bipolar disor-
der (McMahon et al., 2010; Moskvina et al., 2009; Scott et al.,
2009). Interestingly, the miR135a2 gene (chr 12q23.1) is also
located within a highly replicated locus for bipolar disorder,
recurrent major depression, and neuroticism (Curtis et al.,
2003; Dawson et al., 1995; Green et al., 2003). Finally,
miR135b (chr 1q32.1) is located within a third locus for bipolar
disorder (Detera-Wadleigh et al., 1999; Ekholm et al., 2003;
Turecki et al., 1995).
To conclude, we propose that miR135 is an essential regulato-
ry element responsible for maintaining intact serotonergic tone
under normal conditions and essential for the brain response
to antidepressants. Increased levels of miR135 repress an array
of 5HT system-related transcripts, including SERT and presyn-
aptic HTR1A levels, causing an increase in 5HT in the synaptic
cleft, which is associated with decreases in depressive symp-
toms (see schematic model in Figure 7E). These findings may
pave the way to better understanding of the psychopathologies
that are associated with dysregulation of 5HT systems and may
lead to the development of more effective treatments and/or
biomarkers.EXPERIMENTAL PROCEDURES
Methods and materials are described in detail in the Supplemental Experi-
mental Procedures.Mice
For the microRNA microarray of 5HT neurons ePet-EYFP mice (Wylie et al.,
2010) were used. For miR135aOE in 5HT neurons, ePet-Cre mice (Scott
et al., 2005) were crossed with miR135aOEmice (Anderegg et al., 2013). Adult
C57BL/6 male mice were used for the lentiviral experiments and regulation
studies.
Luciferase Assays for Identifying miR-Target Interactions
Normal and mutated 30 UTRs sequences of Slc6a4 and Htr1a were subcloned
into the psiCHECK-2 reporter plasmid (Promega) as previously described
(Haramati et al., 2011). HEK293T cells were transfected with psiCHECK-2
plasmid containing the 30 UTR and the overexpressing vector for a specific
miRNA. Twenty-four hours after transfection, cells were lysed and luciferase
reporter activities were assayed as previously described (Kuperman et al.,
2011).
Chronic Social Defeat and Antidepressant Treatment
Mice were subjected to a social defeat protocol as previously described (Elliott
et al., 2010). Mice received intraperitoneal injection of the tricyclic, imipramine,
the SSRI, fluoxetine, or the NRI, reboxetine (20 mg/kg in saline), or saline.
Brain Microdissection, RNA Extraction, and Real-Time PCR
Brain samples were taken from mice raphe nuclei using an acryl brain matrix
(Stoelting, 51380) and blunted 14G. mRNAs including microRNAs were iso-
lated using miRNeasy mini kit (QIAGEN) and treated using miScript reverse
transcription kit to generate cDNA. Samples were then analyzed using
miScript SYBR Green PCR kit (QIAGEN) according to the manufacturer’s
guidelines in AB 7500 thermocycler (Applied Biosystems).
Western Blot
Protein was purified in RIPA buffer, separated by electrophoresis on 10%
SDS-polyacrylamide gel, and transferred onto nitrocellulose membranes.
Membrane was probed with antibodies against SERT, GFP, or bACTIN and
incubated with peroxidase labeled antibodies followed by visualization with
ECL and quantifications using ImageJ software.
Behavioral Assessments
The open-field, dark-light transfer, and elevated plus-maze tests for anxiety-
like behaviors were performed as previously described (Sztainberg et al.,
2011). Mice locomotion was quantified using a video tracking system (Video-
Mot2; TSE). Depression-like behaviors were assessed using the forced swim
and social avoidance tests performed as previously described (Krishnan
et al., 2007) and automatically scored using EthoVision XT (Noldus).
miR135 Knockdown Lentiviral Production and Intracerebral
Injections
miR135 knockdown (KD) plasmid and commercial scrambled control were
purchased from GeneCopeia (USA). Recombinant lentiviruses were produced
by transient transfection in HEK293T cells, as described previously (Tiscornia
et al., 2006). For surgery and lentiviral delivery, mice were placed on a stereo-
taxic apparatus under general anesthesia as previously described (Lebow
et al., 2012) and the lentiviral preparation was delivered to the DR: ML
0 mm; AP 4.6 mm; DV 3.9 mm in 30 tilt. After recovery, mice were
subjected to behavioral studies and later anesthetized and perfused with
4% PFA. The fixed brains were serially sectioned in order to confirm the loca-
tion of the injection site, using immunohistochemistry as described previously
(Regev et al., 2011).
HPLC-ED Analysis of 5HT and 5-HIAA Concentrations
Microdissections followed by high-performance liquid chromatography with
electrochemical detection (HPLC-ED) as previously described (Neufeld-Co-
hen et al., 2010, Evans et al., 2008).
Human Sample Studies
Case Control Study
Patients recruited from the Max-Planck Institute of Psychiatry were selected
as described inMenke et al. (2012). Total RNAwas isolated using the PAXgeneNeuron 83, 344–360, July 16, 2014 ª2014 Elsevier Inc. 357
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microRNA 135 and 5HT-Related PsychopathologiesBlood RNA Kit (QIAGEN). The studies were conducted in accordance with the
Declaration of Helsinki and its amendments and approved by Max-Planck
Institute of Psychiatry.
Cognitive Behavioral Therapy versus SSRI Study
Patients treated with cognitive behavioral therapy (CBT) or escitalopram had
blood drawn for RNA at baseline and after treatment as previously described
(Dunlop et al., 2012). Whole blood was extracted using the Tempus Spin RNA
Isolation Reagent kit (Applied Biosystems). Declaration of Helsinki and its
amendments and approved by Emory University School of Medicine.
Suicide versus Control Study
Brains obtained from the University Medical School in Budapest as previously
described (Merali et al., 2006). Declaration of Helsinki and its amendments and
approved by Colorado Institutional Review Board.
Statistical Analysis
To test for statistical significance, we used Student’s t test, one-way ANOVA,
two-way ANOVA, and repeated-measure analysis as appropriate using Jmp7
software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.05.042.
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